[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002005870A3 - Kits and compositions supporting intracranial perfusions - Google Patents

Kits and compositions supporting intracranial perfusions Download PDF

Info

Publication number
WO2002005870A3
WO2002005870A3 PCT/US2001/022539 US0122539W WO0205870A3 WO 2002005870 A3 WO2002005870 A3 WO 2002005870A3 US 0122539 W US0122539 W US 0122539W WO 0205870 A3 WO0205870 A3 WO 0205870A3
Authority
WO
WIPO (PCT)
Prior art keywords
components
compositions
kit
nutrient
constituent
Prior art date
Application number
PCT/US2001/022539
Other languages
French (fr)
Other versions
WO2002005870A2 (en
Inventor
David P Hesson
Glenn David Frazer
Timothy J Pelura
Original Assignee
Neuron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Therapeutics Inc filed Critical Neuron Therapeutics Inc
Priority to AU2001276963A priority Critical patent/AU2001276963A1/en
Priority to EP01954737A priority patent/EP1301226A4/en
Publication of WO2002005870A2 publication Critical patent/WO2002005870A2/en
Publication of WO2002005870A3 publication Critical patent/WO2002005870A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0476—Oxygenated solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0693—Brain, cerebrum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided, among other things, is a kit providing pre-measured amounts of components to form a fluorocarbon nutrient emulsion capable of carrying oxygen to living tissue, the kit comprising: constituent solutions, emulsions or particle compositions, which are the constituent compositions, containing pre-measured amounts of components for making the fluorocarbon nutrient emulsion, the constituent compositions comprising: poly-fluorinated, oxygen-carrying compound; a physiologically acceptable emulsifiying agent effective to emulsify the polymer; a nutrient-providing effective amount of carbohydrate; nutrient-providing effective amounts of amino acids or amino acid precursors; an oncotic agent in amount effective to provide, in conjunction with the other components of the solution, a physiologically acceptable oncotic pressure; and sufficient salts and buffering agents to provide a physiological osmotic pressure and physiologically appropriate concentrations of potassium and sodium ions; wherein constituent compositions are selected to allow for sufficient stability of the components to allow for commercial marketing of the kit.
PCT/US2001/022539 2000-07-19 2001-07-18 Kits and compositions supporting intracranial perfusions WO2002005870A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001276963A AU2001276963A1 (en) 2000-07-19 2001-07-18 Kits and compositions supporting intracranial perfusions
EP01954737A EP1301226A4 (en) 2000-07-19 2001-07-18 Kits and compositions supporting intracranial perfusions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61941400A 2000-07-19 2000-07-19
US09/619,414 2000-07-19

Publications (2)

Publication Number Publication Date
WO2002005870A2 WO2002005870A2 (en) 2002-01-24
WO2002005870A3 true WO2002005870A3 (en) 2002-08-15

Family

ID=24481828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022539 WO2002005870A2 (en) 2000-07-19 2001-07-18 Kits and compositions supporting intracranial perfusions

Country Status (3)

Country Link
EP (1) EP1301226A4 (en)
AU (1) AU2001276963A1 (en)
WO (1) WO2002005870A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069711A1 (en) * 2001-03-02 2002-09-12 Neuron Therapeutics, Inc. Gene therapy for neurological tissues
EP2124539A2 (en) 2007-02-17 2009-12-02 President and Fellows of Harvard College Compositions and method for tissue preservation
CA2715634A1 (en) * 2008-02-15 2009-08-27 President And Fellows Of Harvard College Blood substitute solution

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686085A (en) * 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981691A (en) * 1980-04-14 1991-01-01 Thomas Jefferson University Oxygenated fluorocarbon nutrient solution
SE8505048L (en) * 1985-10-25 1987-04-26 Nutritional Int Res Inst NUTRITION EMULSION WITH ACID TRANSPORTING PROPERTIES
WO1988005261A1 (en) * 1987-01-16 1988-07-28 Tops Systems, Inc. Total organ perfusion system
US6500809B1 (en) * 1999-11-12 2002-12-31 Neuron Therapeutics, Inc. Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686085A (en) * 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1301226A4 *

Also Published As

Publication number Publication date
AU2001276963A1 (en) 2002-01-30
EP1301226A4 (en) 2004-07-14
EP1301226A2 (en) 2003-04-16
WO2002005870A2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
CN100381048C (en) Evaluation and preservation solution
ES2052495T5 (en) FLUID THERAPY WITH L-LACTATE AND / OR PIRUVATO ANIONS.
CA1270199A (en) Preservation of living tissue
US6271216B1 (en) Stable solution of hyaluronate in a balanced salt medium
DE19748290B8 (en) Solution for peritoneal dialysis
IE822327L (en) Ophthalmic irrigating solution
AU2696001A (en) Physiological medium for perfusing, preserving and storing isolated cell, tissueand organ samples
BRPI0410116A (en) oral care tablet
JP2020073606A (en) Eye drops for nonionic silicone hydrogel contact lenses
AU2001293851A1 (en) Stabilized hydrogen peroxide solutions
JPH0358935A (en) Stable equilibrium salt medium solution of hyaluronate
KR100278343B1 (en) Artificial saliva
DE50104197D1 (en) Stable infusion solution of diclofenac salts, their preparation and use
WO1996008244A1 (en) Eye drops for repairing corneal disturbance
ATE459336T1 (en) FORMULATION FOR DERMAL USE
WO2002005870A3 (en) Kits and compositions supporting intracranial perfusions
Förster et al. Reduced nitric oxide release causes nitrate tolerance in the intact coronary circulation
AR037964A1 (en) LOW VISCOSITY AND HIGH CONCENTRATION AGRICULTURAL FORMULATIONS
EP0562188B1 (en) Composition for tissues to sustain viability and biological functions in surgery and storage
Bloxam Nutritional aspects of amino acid metabolism: 1. A rat liver perfusion method for the study of amino acid metabolism
AU5233286A (en) Bacteriostatic hemodialysis concentrate
CA2532648A1 (en) A stable clozapine suspension formulation
WO2004075834A3 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same
JP3989574B2 (en) Tooth preservation solution
Breborowicz et al. Intracellular glutathione in human peritoneal mesothelial cells exposed in vitro to dialysis fluid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001954737

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001954737

Country of ref document: EP

ENP Entry into the national phase

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 2001954737

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP